Skip to main content

Table 2 change from baseline to last follow-up in asthma patients with or without ECRS

From: Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

 

all patients, n = 27

ECRS (+) group, n = 16

ECRS (−) group, n = 11

between two groups

baseline

last follow-up

p valuea

at baseline

at last follow-up

p valuea

at baseline

at last follow-up

p valuea

p value‡

blood eosinophil count(/mm3)

873 (1851)

71 (64)

< 0.0001

1219 (2353)

89 (74)

0.0004

338 (364)

44 (31)

0.005

0.0049

serum IgE (IU/ml)

485 (713)

305 (583)

0.016

440 (415)

261 (263)

0.0052

505 (992)

367 (873)

0.95

0.15b

FeNO (ppb)

62 (57)

44 (33)

0.056

84 (62)

53 (37)

0.021

32 (24)

32 (24)

0.53

0.007b

 —Δ%FeNO (%), (range)

0.7 (69.2), (−68—180)

−19 (57), (−68—157)

 

30 (77), (−53—180)

 

0.023

ACT (pts)

15.2 (5.1)

19.5 (5.2)

0.0005

16.3 (5.5)

21.7 (4.8)

0.0023

13.6 (4.2)

16.4 (4.2)

0.066

0.16b

 —ΔACT (pts), (range)

5.3 (4.5), (−4—16)

 

5.4 (5.4), (−3—16)

 

2.7 (4.4), (−4—9)

 

0.24

%FVC (%)

91.1 (14.8)

99.2 (17.5)

0.031

94.7 (14.9)

100.3 (12.9)

0.14

85.1 (13.2)

97.7 (23.8)

0.09

0.16b

%FEV1 (%)

83.3 (27.6)

83.9 (24.2)

0.62

77.4 (24.5)

79.0 (19.9)

0.36

92.1 (30.7)

91.5 (29.3)

0.44

0.35b

FEV1 / FVC (%)

71.1 (13.3)

68.9 (12.9)

0.32

66.6 (12.8)

65.2 (12.5)

0.78

77.8 (11.6)

74.6 (11.8)

0.11

0.026b

%PEF (%)

86.2 (28.2)

89.4 (23.6)

0.011

82.3 (30.8)

85.3 (24.0)

0.011

92.1 (24.1)

95.9 (22.7)

0.53

0.29b

V50/V25

3.5 (1.1)

3.5 (1.1)

0.61

3.5 (1.2)

3.1 (0.9)

0.81

3.5 (1.1)

4.1 (1.1)

0.26

0.78b

daily dose of OCS (mg)§, (range)

8.4 (5.6), (0.5—20) (n = 16)

5.0 (5.8), (0—20) (n = 16)

0.0032

7.0 (4.8), (0.5—15) (n = 10)

2.0 (2.4), (0—6) (n = 10)

0.008

10.8 (6.5), (5—20) (n = 6)

10.0 (6.5), (2.5—20) (n = 6)

0.16

0.29b

 —ΔOCS (%), (range)

−48.6 (43.3), (−100—0)

−71.3 (37.0), (−100—0)

−10.7 (20.1), (−50—0)

0.006

exacerbation (/year), n

5.6 (4.9)

2.9 (3.7)

0.002

5.6 (5.6)

2.4 (3.3)

0.01

5.5 (3.9)

3.6 (4.2)

0.0498

0.77b

 —Δexacerbation (%), (range)

−44.7 (61.4), (−100—125)

− 48.4 (62.6),(− 100—125)

−39.9 (62.6), (− 100—100)

0.82

  1. ECRS eosinophilic chronic rhinosinusitis, NA not available, ACT Asthma Control Test Δ: change from baseline to the last follow-up Data presented as mean (standard deviation), unless otherwise stated. Blood eosinophil counts at last follow-up were examined at 3 months(median, range 1–6). Serum IgE tests at last follow-up were examined at 6 months(median, range 2–6)
  2. FeNO tests at last folloow-up were examined at 9 months(median, range 1–12). Asthma Control Tests(ACT) score at last follow-up was examined at 6 months(median, range 2–12)
  3. Pulmonary function tests at last follow-up were comducted at 4 months(median, range 2–10)
  4. aWilcoxon signed rank test ‡ Mann-Whitney U test § Oral corticosteroid(OCS) doses are provided as prednisone equivalents (mg). b at baseline
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us